Columbia Pays Millions to Settle Fraud Claim

The university has agreed to pay more than $9 million to resolve a lawsuit filed by the US government over the submission of false claims regarding federal research funds.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, LONPICMANColumbia University has agreed to pay more than $9 million to settle a US government lawsuit alleging that the institution’s Mailman School of Public Health, which oversaw grant administration at the International Center for AIDS Care and Treatment Programs (ICAP), wrongly charged many grants awarded to the center for work that did not relate to the funded projects. The university admitted that it faked cost reports for a federal grant that was supposed to fund work at ICAP. Columbia settled the lawsuit, which stemmed from complaints filed in 2011 by whistleblower Craig Love, ICAP’s former director of finance, on Tuesday (October 28), the same day it was filed. “We admire and applaud Columbia’s work in combating AIDS and HIV,” Manhattan U.S. Attorney Preet Bharara said in a statement announcing the settlement. “But grantees cannot disregard the terms under which grant money is provided.”

Thomas O’Donnell, the special agent in charge of investigating Columbia for the US Department of Health and Human Services (HHS), agreed. “Violating rules designed to protect HIV-AIDS grant programs leads to wasteful spending, squandering vital funds that could be used to help end this worldwide epidemic,” he told Courthouse News Service. “As HHS is the largest grant-making organization in the federal government, HHS is committed to protecting these grants and will work tirelessly to ensure all money is used properly.”

“New controls were implemented in 2012 to better support ICAP in continuing its widely respected public health mission,” Columbia said in a statement, Reuters reported.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of small blue creatures called Nergals. Some have hearts above their heads, which signify friendship. There is one Nergal who is sneezing and losing health, which is denoted by minus one signs floating around it.
June 2025, Issue 1

Nergal Networks: Where Friendship Meets Infection

A citizen science game explores how social choices and networks can influence how an illness moves through a population.

View this Issue
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo
Unraveling Complex Biology with Advanced Multiomics Technology

Unraveling Complex Biology with Five-Dimensional Multiomics

Element Bioscience Logo
Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Twist Bio 
The Scientist Placeholder Image

Seeing and Sorting with Confidence

BD

Products

The Scientist Placeholder Image

Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity 

The Scientist Placeholder Image

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

agilent-logo

Agilent Announces the Enhanced 8850 Gas Chromatograph

parse-biosciences-logo

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies